• Call Us! 786.749.1221

  • NASDAQ: SMFL $0.15 ( 0.40161327% )

Press Release

Smart for Life Releases Online Investor Fact Sheet

Smart for Life Releases Online Investor Fact Sheet 1920 1080 Smart for Life, Inc.

Company Provides Additional Resources for Investors on its Corporate Website

Miami, FL – March 21, 2023 – Globe Newswire – Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a high growth global leader in the health & wellness sector, marketing and manufacturing nutritional foods and supplements worldwide, announced today the publication of its recently updated investor fact sheet for the first half of 2023.

As stated more fully in the updated material, the nutraceutical industry is highly fragmented and is experiencing significant growth. The nutraceutical industry is expecting to reach $720 billion in size by 2027. Leveraging its buy-and-build M&A strategy that is focused on both vertical and horizontal integration, Smart for Life, Inc. and its management team believes it is poised to benefit from the projected rapid expansion of these dynamic industry trends going forward.

The updated investor fact sheet provides an overview of Smart for Life’s business model and the company’s growth potential, in addition to serving as a resource for both existing shareholders and prospective investors.

Smart for Life’s updated investor fact sheet can be viewed and downloaded by navigating to: https://www.smartforlifecorp.com/ifs.

As the Company expands its awareness initiatives going forward, investors can also find the most current information and material through Smart for Life’s investor portal and can sign up for news alerts at: https://www.smartforlifecorp.com/investor-center/.

About Smart for Life, Inc.
Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on Health & Wellness. Structured as a publicly held global holding company, the Company is executing a buy-and-build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-six months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceautamed Worldwide. For more information about Smart for Life, please visit: www.smartforlifecorp.com.

Video regarding the Company’s manufacturing facility at Bonne Santé Natural Manufacturing is available at: www.bonnesantemanufacturing.com/video.

Investor material and a Fact Sheet with additional information about Smart for Life is available at: www.smartforlifecorp.com/investor-center.

Forward-Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations of Smart for Life’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease

Investor Relations Contact
Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Smart for Life to Hold Shareholder Meeting on March 15, 2023

Smart for Life to Hold Shareholder Meeting on March 15, 2023 1920 1080 Smart for Life, Inc.

Shareholder Meeting Follows the Company’s Successful Hearing with the Nasdaq Hearings Panel

Miami, FL – February 13, 2023 – Globe Newswire – Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, announced today that the Company filed a definitive proxy statement with the Securities and Exchange Commission in connection with a special meeting of stockholders (the “Special Meeting”) scheduled on March 15, 2023. The Special Meeting is being held to vote on various matters, including to effect an increase in the total number of authorized shares of common stock of the Company and to effect a reverse stock split of the issued and outstanding shares of common stock.

If approved by the stockholders and implemented by the Company’s board of directors, the reverse stock split is primarily intended to increase the price per share of the Company’s common stock to enable it to comply with the Nasdaq continued listing requirements. Each shareholder’s pro rata percentage would remain unchanged. Additionally, the Company believes increasing the per-share market price of its common stock would make the Company more attractive to a wider range of institutional investors and brokerage firms otherwise restricted due to share price requirements.

“We remain committed to growing Smart for Life toward our stated objective of $300 million in revenue through our high-growth M&A initiatives and it is critical for the Company to preserve its Nasdaq listing to achieve this goal,” stated Darren Minton, Smart for Life’s Chief Executive Officer. “We continue to execute on our plans, and we believe these measures will set the foundation for successful value creation as we carry out our proactive acquisition strategy, targeting accretive cash flow positive companies and driving the long-term growth of Smart for Life.”

The definitive proxy statement and other relevant materials will be mailed to stockholders of the Company as of the record date of February 3, 2023. Investors and security holders will also be able to obtain these documents at the SEC’s website, www.sec.gov.

About Smart for Life, Inc.
Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a publicly held global holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-nine months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceautamed Worldwide. For more information about Smart for Life, please visit: www.smartforlifecorp.com.

Video regarding the Company’s manufacturing facility at Bonne Santé Natural Manufacturing is available at: www.bonnesantemanufacturing.com/video.

Investor material and a Fact Sheet with additional information about Smart for Life is available at: www.smartforlifecorp.com/investor-center.

Forward-Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations of Smart for Life’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

Investor Relations Contact
Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Smart for Life Provides an Update on Nasdaq Listing

Smart for Life Provides an Update on Nasdaq Listing 1920 1080 Smart for Life, Inc.

Company’s Successful Hearing with Nasdaq Hearings Panel Results in Extension until May 30, 2023 to Regain Compliance

Miami, FL – February 1, 2023 – Globe Newswire – Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, announced today that the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) on January 25, 2023, notifying the Company that the Nasdaq Hearings Panel (“Panel”) has granted an exception from two continued listing standards, Nasdaq’s stockholders’ equity requirement of $2,500,000, as set forth in Listing Rule 5550(b) (the “Equity Rule”), and Nasdaq’s $1.00 bid price requirement, as set forth in Listing Rule 5550(a)(2) (the “Bid Price Rule”), until May 30, 2023.

As previously disclosed, on December 5, 2022, the Company requested a hearing with the Panel, which was held on January 19, 2023. As a result of the Panel’s decision, the Company now has until May 30, 2023 to regain compliance with the Equity Rule and the Bid Price Rule.

This news was preceded by the Company’s successful conversion of approximately $2.5 million of debt to equity and the Company’s announcement of its upcoming Annual Shareholder meeting scheduled for March 15, 2023.

“We are very pleased with the Panel’s decision to grant us an extension to regain compliance,” stated Darren Minton, Smart for Life’s Chief Executive Officer. “We are continuing to implement our high-growth acquisition strategy and have several potential acquisitions in the pipeline. We have a strong track record of acquiring complementary businesses at attractive valuations and continue to grow toward our goal of $100 million in revenue in the next 12 months.”

About Smart for Life, Inc.
Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a publicly held global holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-nine months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceautamed Worldwide. For more information about Smart for Life, please visit: www.smartforlifecorp.com.

Video regarding the Company’s manufacturing facility at Bonne Santé Natural Manufacturing is available at: www.bonnesantemanufacturing.com/video.

Investor material and a Fact Sheet with additional information about Smart for Life is available at: www.smartforlifecorp.com/investor-center.

Forward-Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations of Smart for Life’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

Investor Relations Contact
Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Smart for Life CEO Issues Year-End Letter to Shareholders

Smart for Life CEO Issues Year-End Letter to Shareholders 1920 1080 Smart for Life, Inc.

2022 Marked Transformative Year for Smart for Life; Built a Solid Foundation Through Acquisitions and Anticipates Significant Growth in 2023

Miami, FL – January 12, 2023 – Globe Newswire – Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today provided the following letter to shareholders from the Company’s CEO, Darren Minton:

“2022 was truly a transformative year for Smart for life and as we look toward a promising year ahead, I am proud to reflect on all that we have achieved. In the beginning of 2022, we completed our Initial Public Offering and raised gross proceeds of $14.4 million. We have now completed five major acquisitions since our formation which not only validates our ability to acquire accretive businesses at attractive multiples but also our ability to successfully integrate these companies within our organization. Although 2022 has certainly been a tumultuous year in the capital markets, our proactive “Buy and Build” strategy is working—we are currently generating pro forma revenues in excess of $30 million and anticipate expanding to over $100 million in annualized revenues in the next twelve months based on anticipated acquisitions and organic growth.  In addition, as we have publicly announced, we have an objective of achieving $300 million in revenues within the next 36 months.

Through our subsidiaries, we boast a dynamic, exciting mix of brands and capabilities including Ceautamed Worldwide LLC, GSP Nutrition Inc. (which owns a license in the U.S. and Canada for the exclusive use of certain of the Sports Illustrated brands in the fields of dietary and nutritional supplements), Doctors Scientific Organica, LLC, Bonne Santé Natural Manufacturing, Inc. and Nexus Offers, Inc. Our current businesses include two state-of-the-art FDA-certified contract manufacturing facilities, spanning an aggregate of 60,000 sq. ft., along with consumer brands, digital marketing services, and licensing agreements. We offer a variety of cutting-edge formulary and manufacturing capabilities including capsules, tablets, powders, health bars, baked goods, functional foods, and other product types and delivery methods.

We achieved several noteworthy milestones in 2022:

  • Launched new line of Greens First protein bars
  • Achieved strong revenue growth: Q3 2022 revenues increased 59.1% year-over-year to $5.4 million due to successful acquisition strategy; Q3 2022 profit margin increased to 49.1%, versus 42.6% for the same period last year
  • Initiated capital restructuring designed to increase shareholders’ equity and contribute toward our continued Nasdaq listing requirements
  • Opened new corporate headquarters, consolidated operations aimed at delivering greater savings and efficiencies at scale
  • Executed Letter of Intent for strategic co-venture with Cosmos Health, Inc. (Nasdaq: COSM) to cross market products and services in their reciprocal markets
  • Announced Letter of Intent to acquire a premier eCommerce nutraceuticals company with operations in North America; acquisition is expected to add over $12 million of revenue and to be accretive to earnings
  • Formed Smart Acquisition Group, LLC to accelerate M&A activities; named Stuart Benson, JD as Managing Director
  • Completed strategic acquisition of Ceautamed Worldwide LLC owner of Greens First Brand; expected to be highly synergistic and accretive, while adding established medical distribution channels and expanding product portfolio
  • Partnered with Milk Dust for manufacturing of its proprietary products designed to support mother’s breast milk production during baby formula shortage
  • Aided shipment of over 100,000 meal replacement bars to Ukraine to help those in need
  • Selected by Amazon to launch various Smart for Life products in Singapore
  • Acquired Sports Illustrated™ trademark rights as described above

In summary, Smart for Life represents an exciting opportunity to invest in a dynamic, innovative, proactive organization capitalizing on the fragmented yet rapidly growing nutraceutical market. We believe our proactive acquisition strategy, targeting accretive cash flow positive companies, combined with strategies to enhance organic growth, represents the best path to drive long-term value for shareholders.  We are extremely well positioned to take advantage of the opportunities in front of us and are excited about the outlook for 2023 and beyond.”

About Smart for Life, Inc.
Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a publicly held global holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-nine months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceautamed Worldwide. For more information about Smart for Life, please visit: www.smartforlifecorp.com.

Video regarding the Company’s manufacturing facility at Bonne Santé Natural Manufacturing is available at: www.bonnesantemanufacturing.com/video.

Investor material and a Fact Sheet with additional information about Smart for Life is available at: www.smartforlifecorp.com/investor-center.

Forward-Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations of Smart for Life’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

Investor Relations Contact
Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Smart for Life Announces Launch of Greens First Protein Bars

Smart for Life Announces Launch of Greens First Protein Bars 1920 1080 Smart for Life, Inc.

New Line of Protein Bars Specifically Formulated with the Greens First PRO Line, Provides a Nutrient Dense Meal Replacement with 54 Super Foods, Expected Launch in Q1 2023

Miami, FL – December 27, 2022 – Globe Newswire – Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today announced that it is launching a line of Greens First protein bars, specifically created with the flagship Greens First PRO formula.

Greens First protein bars represent a brand new premium nutritious protein bar, combined with the Greens First PRO powder, which is fortified with whole plants, vegetables and fruits that helps to strengthen the body and complete a balanced diet. These whole food supplements contain the naturally occurring nutrients that that are intrinsic to fruits, vegetables and superfoods. Each bar features 15 grams of protein while maintaining a high fiber but low sugar profile, is antioxidant & collagen infused and designed to keep you energized.

Launch flavors will include Mint Chocolate Chip and Double Chocolate with additional flavors expected to join the line-up after feedback from the initial launch.

“We are thrilled to launch this innovative line of Greens First protein bars, based on the success of our PRO line of products,” stated Darren Minton, Smart for Life’s Chief Executive Officer. “Each of our bars has over 15 grams of protein and nutrients to power your day, along with a combination of ingredients that are engineered to provide a great texture and taste. We are looking forward to sharing them with our dedicated customers.”

The Greens First brand will now have nutritious protein bars that address energy and performance. The bars contain certified organic fruits, vegetables, and barley grass which are first juiced, then spray dried at low temperatures, leaving all the important nutrients and live enzymes intact. The bars are formulated to be clean and energizing, with no sucralose, no preservatives, and non-GMO.

“Now that we are part of the Smart for Life family, we are pleased to launch these Greens First protein bars, which combine the benefits of our PRO products that are made easy to digest for quick absorption and assimilation of all the nutrients, in a nutritious bar format,” stated Ryan Benson, CEO of Ceautamed Worldwide. “This compliments our traditional powdered drink format that we have distributed over the past 20 years and gives our loyal customers another way to enjoy our products on the run.”

The Greens First PRO Products are professional-grade formulas with 54 different superfoods for practitioners who are looking for pure, whole food formulations. These professional products were created to help support and alkalize the body’s pH balance, assist in the reduction of the inflammatory process, help quench all 5 of the major free radicals and nourish the body with the antioxidant and phytonutrient power of more than 15 servings of fruits, vegetables, superfoods, probiotics and digestive enzymes.

Greens First protein bars will be available in the first quarter of 2023. To learn more about the various products offered under the Greens First line of vitamins and supplements, please visit: www.greensfirst.com.

About Ceautamed Worldwide
Ceautamed Worldwide, a subsidiary of Smart for Life, Inc., is based in Boca Raton, Florida, and was formed in 2009. Ceautamed owns the Greens First line of branded products which have been specifically marketed to the healthcare provider sector. These vitamins and supplements have been sold on a business-to-business basis, direct-to-consumer as well as sold utilizing an international medical distribution company pursuant to a long-term contract. Ceautamed’s Greens First brand also maintains an online presence at: www.greensfirst.com.

About Smart for Life, Inc.
Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a publicly held global holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-nine months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceautamed Worldwide. For more information about Smart for Life, please visit: www.smartforlifecorp.com.

Video regarding the Company’s manufacturing facility at Bonne Santé Natural Manufacturing is available at: www.bonnesantemanufacturing.com/video.

Investor material and a Fact Sheet with additional information about Smart for Life is available at: www.smartforlifecorp.com/investor-center.

Forward-Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations of Smart for Life’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

Investor Relations Contact
Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Smart for Life Announces Capital Restructuring Designed to Address Nasdaq Listing Requirements and Unlock Shareholder Value

Smart for Life Announces Capital Restructuring Designed to Address Nasdaq Listing Requirements and Unlock Shareholder Value 1920 1080 Smart for Life, Inc.

Includes $1.0M Private Placement with Accredited Institutional Investors; and Conversion of $2.5M of Debt to Equity

Restructuring Enhances Balance Sheet and Increases Shareholders’ Equity for Nasdaq Compliance

Miami, FL – December 9, 2022 – Globe Newswire – Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today announced a series of agreements designed to enhance the capital structure, increase shareholders’ equity and contribute toward our continued Nasdaq listing requirements. First, the Company has entered into a securities purchase agreement with investors whereby the Company issued the investors an aggregate of 1,282,896 shares of common stock and prefunded warrants to purchase an aggregate of 1,574,248 shares of common stock for an aggregate purchase price of $1,000,000, or $0.35 per share.

The investors were previously issued 12% unsecured subordinated convertible debentures in the aggregate principal amount of $2,250,000, which were convertible into shares of common stock at a conversion price of $1.00 per share. In connection with the private placement, the investors agreed to convert all outstanding principal and interest on the debentures, in the amount of $2,542,500, into an aggregate of 2,542,501 shares of common stock in accordance with the terms of the debentures. In consideration for, and as an inducement for the agreement of the investors to convert the debentures, the Company also issued the investors prefunded warrants to purchase an aggregate of 4,721,787 shares of common stock.

The investors were also previously issued warrants to purchase common stock at $6.25 per share, which contained a full ratchet antidilution adjustment for securities issuances below such price. As a result of the private placement at $0.35, the exercise price of these warrants was reduced to $0.35 and the number of shares underlying the warrants increased in accordance with the full ratchet antidilution adjustment. Following such adjustment, the investors agreed to amend the terms of the warrants, including the removal of the feature of the full ratchet antidilution adjustment that required the issuance of additional shares upon a triggering event such that the exercise price would be reduced upon a triggering event but the number of shares underlying the warrant would not be further increased.

“We believe these latest agreements significantly improve and simplify our capital structure by removing anti-dilutive provisions in our warrants, while providing us additional working capital to execute our growth strategy and increasing our shareholders’ equity, a key requirement to maintain our listing on Nasdaq,” stated Darren Minton, CEO of Smart for Life. “We continue to make progress towards our goal of reaching $100 million in annualized revenue in 2023 and believe these latest steps will help unlock significant long-term value for shareholders through an enhanced capital structure.”

Additional details on the transaction are available in the Company’s Form 8-K, which has been filed with the Securities and Exchange Commission and is available on the Company’s website.

About Smart for Life, Inc.
Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a publicly held global holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-nine months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceautamed Worldwide. For more information about Smart for Life, please visit: www.smartforlifecorp.com.

Video regarding the Company’s manufacturing facility at Bonne Santé Natural Manufacturing is available at: www.bonnesantemanufacturing.com/video.

Investor material and a Fact Sheet with additional information about Smart for Life is available at: www.smartforlifecorp.com/investor-center.

Forward-Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations of Smart for Life’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

Investor Relations Contact
Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Smart for Life Announces New Corporate Headquarters

Smart for Life Announces New Corporate Headquarters 1920 1080 Smart for Life, Inc.

Consolidation of Corporate Operations Will Drive Greater Efficiencies and Cost Savings

Miami, FL – December 5, 2022 – Globe Newswire – Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today announced the consolidation of operations with relocation of its corporate headquarters to 990 S Rogers Circle, Suite 3, Boca Raton, FL 33487. Consistent with the Company’s M&A strategy and goal of streamlining operations to leverage synergies of its combined companies, the new headquarters consists of corporate offices, a new fulfillment and call center, as well as additional warehouse space.

“Relocation of our corporate headquarters is another key step in executing operating efficiency and cost-savings strategies, as we continue to drive growth both organically and through acquisitions,” stated Darren Minton, CEO of Smart for Life. “We have been operating multiple offices in Southern Florida, in addition to a third-party fulfillment center, all of which will now be under one roof. We also expect to benefit from further economies of scale as the new headquarters will also provide us with the capacity to support future acquisitions which we believe is important given our track record of acquiring complementary businesses at attractive valuations. We expect that the consolidation of our operations should result in improved profitability in future quarters as we continue to reduce costs and grow our top-line revenue. We look forward to making progress towards our goal of reaching $100 million in annualized revenue in 2023.”

About Smart for Life, Inc.
Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a publicly held global holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-nine months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceautamed Worldwide. For more information about Smart for Life, please visit: www.smartforlifecorp.com.

Video regarding the Company’s manufacturing facility at Bonne Santé Natural Manufacturing is available at: www.bonnesantemanufacturing.com/video.

Investor material and a Fact Sheet with additional information about Smart for Life is available at: www.smartforlifecorp.com/investor-center.

Forward-Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations of Smart for Life’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

Investor Relations Contact
Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Smart for Life Announces Q3 2022 Financial Results

Smart for Life Announces Q3 2022 Financial Results 1920 1080 Smart for Life, Inc.

Revenue Increases 59.1% Year-Over-Year to $5.4 Million for the Third Quarter of 2022 Due to Successful Acquisition Strategy

Gross Profit Margin Increases to 49.1% Versus 42.6% for the Same Period Last Year

Miami, FL – November 14, 2022 – Globe Newswire – Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today provided a business update and reported financial results for the third quarter ended September 30, 2022.

Darren Minton, CEO of Smart for Life, stated, “We continue to successfully implement our acquisition strategy and generate solid year-over-year growth with revenues for Q3 2022 increasing by 59.1% to $5.4 million and revenues for the first 9 months of 2022 increasing by 194.0% to $14.1 million. These results do not include the full quarter of revenue for Ceautamed Worldwide (Ceautamed), which we acquired on July 29, 2022. On a proforma basis, assuming we had acquired Ceautamed on July 1, 2022, our total revenue for the quarter would have been $5.8 million. As a result, we estimate our annualized revenue run rate is now in excess of $23 million.”

“We are progressing with the integration of Ceautamed, a premier nutritional supplement company and owner of the Greens First brand. Ceautamed represents our fifth acquisition to date and brings with it solid financials, positive EBITDA, the addition of experienced management, a successful medical distribution channel, migration of substantial contract manufacturing business to our Miami-based manufacturing facility and, most importantly, the addition of the Greens First brand and over 45 SKUs to our growing portfolio of great brands and products. We have already started to benefit from operating efficiencies and cost savings as we migrate Ceautamed’s contract manufacturing to our Miami-based manufacturing facility.”

“We also announced a Letter of Intent (LOI) to acquire a premier eCommerce nutraceuticals company with operations in North America, which would represent our largest acquisition to date. The target business has established a fantastic brand in the health and wellness sector and should be highly synergistic with our existing distribution channels and in-house manufacturing capabilities. Notably, they achieved over $15 million in sales for the trailing twelve months and have been consistently profitable.”

“We are continuing to implement our high-growth acquisition strategy, and we expect that the consolidation of our operations should result in improved profitability in future quarters as we continue to reduce costs and grow our top-line revenue. Overall, we now have a proven track record of acquiring complementary businesses at attractive valuations, which is especially noteworthy, as we grow toward our stated goal of $100 million in revenue in the next 12 months.”

Financial Results
Revenues increased to $5.4 million in Q3 2022 compared to $3.4 million for Q3 2021, an increase of $2.0 million, or 59.1%. The increase was primarily due to the acquisitions of Doctors Scientific Organica, LLC, Nexus Offers, Inc. and GSP Nutrition Inc. that were completed in the third and fourth quarters of 2021 and the acquisition of Ceautamed that was completed in the third quarter of 2022. Gross profit increased to $2.6 million in Q3 2022 compared to approximately $1.4 million for same period last year, an increase of approximately $1.2 million. Net loss attributable to common shareholders was $1.9 million in Q3 2022 compared to a net loss of $2.4 million in Q3 2021, a decrease of $408 thousand, or 17.3%.

Revenues increased to $14.1 million for the nine months ended September 30, 2022 compared to $4.8 million for the nine months ended September 30, 2021, an increase of $9.3 million, or 194.0%, due to the acquisitions completed in 2021 and the acquisition of Ceautamed that was completed in the third quarter of 2022. Gross profit increased to $5.9 million for the nine months ended September 30, 2022 compared to approximately $1.5 million for same period last year, an increase of $4.5 million or 304.6%. Net loss attributable to common shareholders was $21.9 million for the nine months ended September 30, 2022 compared to $4.1 million for same period last year, which was largely driven by increases in salaries, professional fees and other general and administrative expenses related to the expansion of our business and our initial public offering, as well as a significant increase in interest expense.

EBITDA and Adjusted EBITDA
The Company reported Adjusted EBITDA of ($0.9) million in Q3 2022, as compared to Adjusted EBITDA of ($1.2) million for Q3 2021. For the nine months ended September 30, 2022, the Company reported Adjusted EBITDA of ($6.0) million versus Adjusted EBITDA of ($2.7) million for the same period last year. The Company defines EBITDA as earnings before interest, taxes and depreciation and amortization. Adjusted EBITDA is defined as EBITDA before other expense, change in value of derivative liability and gain on debt extinguishment. Both EBITDA and Adjusted EBITDA are not measures of performance calculated in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”), and should not be considered in isolation of, or as a substitute for, earnings as an indicator of operating performance or cash flows from operating activities as a measure of liquidity. The Company believes the presentation of EBITDA and Adjusted EBITDA is relevant and useful by enhancing the readers’ ability to understand the Company’s operating performance. The Company’s management utilizes EBITDA as means to measure performance. The Company’s measurements of EBITDA and Adjusted EBITDA may not be comparable to similar titled measures reported by other companies. The table below reconciles EBITDA and Adjusted EBITDA, both non-GAAP measures, to GAAP numbers for net loss for the three and nine months ended September 30, 2022 and 2021.

About Smart for Life, Inc.
Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a publicly held global holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-nine months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceautamed Worldwide. For more information about Smart for Life, please visit: www.smartforlifecorp.com.

Video regarding the Company’s manufacturing facility at Bonne Santé Natural Manufacturing is available at: www.bonnesantemanufacturing.com/video.

Investor material and a Fact Sheet with additional information about Smart for Life is available at: www.smartforlifecorp.com/investor-center.

Forward-Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations of Smart for Life’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

Investor Relations Contact
Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Cosmos Health and Smart for Life Execute Letter of Intent for Strategic Global Co-Venture

Cosmos Health and Smart for Life Execute Letter of Intent for Strategic Global Co-Venture 1920 1080 Smart for Life, Inc.

LOI Calls for the Provision of SMFL Pan-European Access and COSM North American Access for Products and Services

 Miami, FL and Chicago, IL– October 27, 2022 – Globe Newswire – Cosmos Holdings d/b/a Cosmos Health, Inc.(“Cosmos”) (Nasdaq: COSM) and Smart for Life, Inc. (Nasdaq: SMFL), both high growth leaders in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements today announced that they have executed a non-binding Letter of Intent for a strategic co-venture agreement to cross market products and services in their reciprocal markets. The announcement was made jointly by Greg Siokas, CEO of Cosmos and A.J. Cervantes, Jr., Chairman of Smart for Life.  The Letter of Intent was executed on October 27, 2022.  The terms of the letter of intent are anticipated to become the subject of a definitive agreement between the parties within the next thirty days.

“We are two high growth companies in the Health & Wellness industry with the primary distinction being our respective markets, with Cosmos serving the EU and UK markets and Smart for Life serving the North American markets,” said Mr. Cervantes. “Greg and I have spent time exploring the prospective benefits to be derived from our cross-border relationship, both short term and long term. It is obvious when looking at the two companies, the synergies that exist.”

Greg Siokas, CEO of Cosmos noted, “We believe our EU distribution organization can achieve significant revenues with the Smart for Life brands. Our management team is hard at work, developing the various synergies with Smart for Life products which may realize significant commercial success through the Cosmos distribution channels.”

Mr. Cervantes concluded, “We believe that, in particular, Cosmos’ two proprietary brands ‘Sky Premium Life’ and ‘Mediterranation’, can be potential high revenue products marketed through the Smart for Life distribution channels in the US.”

About Smart for Life, Inc.
Smart for Life, Inc. (Nasdaq: SMFL) is a high growth global leader in the Health & Wellness sector, marketing and manufacturing nutritional foods and supplements worldwide. Structured as a publicly held international holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-six months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition/Sports Illustrated Nutrition and Ceautamed Worldwide/Greens First. For more information about Smart for Life, please visit: www.smartforlifecorp.com.

Video regarding the Company’s manufacturing facility at Bonne Santé Natural Manufacturing is available at: www.bonnesantemanufacturing.com/video.

Investor material and a Fact Sheet with additional information about Smart for Life is available at: www.smartforlifecorp.com/investor-center.

About Cosmos Health, Inc.
Cosmos Health Inc. (Nasdaq: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmosholdingsinc.com and www.skypremiumlife.com.

Smart for Life, Inc. Forward-Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations of Smart for Life’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Cosmos Health, Inc. Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could”, are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company’s business, operations and the economy in general, and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Smart for Life Investor Relations Contact
Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com

Cosmos Health Investor Relations Contact
Lytham Partners, LLC
Ben Shamsian
E: shamsian@lythampartners.com
P: 646-829-9701

Smart for Life Appoints Accomplished Finance and Capital Markets Executive Arthur S. Reynolds to Board of Directors

Smart for Life Appoints Accomplished Finance and Capital Markets Executive Arthur S. Reynolds to Board of Directors 1920 1080 Smart for Life, Inc.

Miami, FL –October 21, 2022 – Globe Newswire – Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a global leader in the Health & Wellness sector marketing and manufacturing nutritional supplements and foods worldwide, today announced that Arthur S. Reynolds has been appointed to the Company’s Board of Directors. Mr. Reynolds will serve on the Compensation and Audit Committees and has been appointed Chair of the Audit Committee.

Arthur S. Reynolds is an accomplished international financier bringing more than 35 years of capital markets and financial experience providing cross-border financial consulting services in Europe for clients principally located in the United States. He is the founder of Rexon Limited of London and New York where he has served as managing director. Mr. Reynolds was founder and managing partner of London-based Value Management & Research (UK) Limited. Mr. Reynolds was the founder and served as managing director of Ferghana Financial Services Limited. Prior thereto, Mr. Reynolds held executive positions at Merrill Lynch International Bank Limited, Banque de la Société Financière Européene, J.P. Morgan & Company and Mobil Corporation. Mr. Reynolds previously served on the Board of Directors of ThermoEnergy Corporation, first as Chairman of the Audit Committee, subsequently as Chief Financial Officer, and finally as Chairman. Mr. Reynolds is a member of the Board of the International Festival Society and serves as Chairman of the Elgar Society’s North America Branch. Mr. Reynolds holds an B.A. from Columbia University, a M.A. from Cambridge University, and an M.B.A. in Finance from New York University.

A.J. Cervantes, Jr., Chairman of Smart for Life, stated, “We are delighted to welcome Arthur to the Board of Directors, including his role as Chairman of the audit committee. He brings extensive financial and executive experience across multiple sectors, with particular strength in the international arena, which will be particularly valuable as we expand our global footprint. Having completed five material acquisitions in just the last year alone, and having recently announced our sixth planned acquisition, we are on track to achieve our goal of surpassing a $100 million revenue run rate within the next 12 months. Given our aggressive growth plans, we look forward to benefitting from Arthur’s knowledge, experience, and skills, as we realize the synergies and operating efficiencies across the acquired companies. We also believe his appointment further reflects our commitment to the highest levels of corporate governance.”

Mr. Reynolds further noted, “I am honored to join the Board of Smart for Life at this exciting time, especially given management’s proven track records and the highly fragmented nature of this industry. They have repeatedly demonstrated their ability to acquire complementary businesses at attractive valuations, while driving economies of scale through their state-of-the-art manufacturing facilities. As a result, Smart for Life is rapidly emerging as a leader in the $400 billion nutraceuticals industry, with an impressive array of high quality nutritional foods and supplements. I look forward to leveraging my capital markets and M&A experience to help maximize value for shareholders.”

About Smart for Life, Inc.
Smart for Life, Inc. (Nasdaq: SMFL) is engaged in the development, marketing, manufacturing, acquisition, operation and sale of a broad spectrum of nutritional and related products with an emphasis on health and wellness. Structured as a publicly held global holding company, the Company is executing a Buy-and-Build strategy with serial accretive acquisitions creating a vertically integrated company with an objective of aggregating companies generating a minimum of $300 million in revenues within the next thirty-six months. To drive growth and earnings, Smart for Life is developing proprietary products as well as acquiring other profitable companies, encompassing brands, manufacturing and distribution channels. The Company currently operates five subsidiaries including Doctors Scientific Organica, Nexus Offers, Bonne Santé Natural Manufacturing, GSP Nutrition and Ceutamed Worldwide. For more information about Smart for Life, please visit: www.smartforlifecorp.com.

Video regarding the Company’s manufacturing facility at Bonne Santé Natural Manufacturing is available at: www.bonnesantemanufacturing.com/video.

Investor material and a Fact Sheet with additional information about Smart for Life is available at: www.smartforlifecorp.com/investor-center.

Forward-Looking Statements
This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions and expectations of Smart for Life’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Smart for Life believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Smart for Life does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Smart for Life will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks and uncertainties, some of which are not currently known to us, that may cause Smart for Life’s actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory changes, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer
The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

Investor Relations Contact
Crescendo Communications, LLC
Tel: (212) 671-1021
SMFL@crescendo-ir.com